Earlier this week the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) based primarily on real-world evidence (RWE). The decision reflects the increasing importance of real-world data (RWD) […]
Are you attending the 10th annual national conference of the Swedish Health Economics Association (SHEA) in Gothenburg this week? In that case we really hope that you were able to listen in on Quantify’s Douglas Knutsson yesterday when he presented an excerpt […]
Today we are happy to introduce Philip Gavuzzi who joined the Stockholm team as a Research Analyst last week. Philip has a background in economic analysis and hold […]
Today we are delighted to introduce Ethan O’Leary who joined our Stockholm team as a Research Analyst this Monday!
Ethan is currently finishing his Master’s in Economics from Stockholm School […]
Quantify’s Christoph Abé (PhD) publishes the largest-ever study associating bipolar disorder with abnormal brain changes over time in the renowned journal Biological Psychiatry, using neuroimaging data.
—
Our Lead Analyst, Christoph Abé (PhD) led an international […]
Check out this recent publication from Quantify, presenting a new conceptual framework in psoriasis that differentiates psoriasis severity from disease control (Link to article: https://onlinelibrary.wiley.com/doi/10.1111/bjd.21023https://lnkd.in/gJtZtENB). Authored by Quantify’s CEO Kirk Geale, […]
At Quantify, we work a lot with ICD codes. And we mean a lot! So much, in fact, that we have discovered some pretty obscure codes that you might not be aware […]
The 28th February is #rarediseaseday and we at Quantify want to help spread awareness of this important day as an estimated 300 million people of the world’s population are currently living with a rare disease.
At Quantify we are determined to […]